(Reuters) - The U.S. health regulator's advisers said on Friday that data on Merck's chronic cough drug gefapixant does not provide sufficient evidence to prove its clinical benefit for patients.

Nov 15 (Reuters) - U.S. Food and Drug Administration’s reviewers on Wednesday flagged concerns that data on Merck’s chronic cough drug might not be sufficient to prove meaningful benefit ...

The U.S. Food and Drug Administration's (FDA) panel voted 12 to 1 against the late-stage data submitted by Merck for the drug gefapixant, which showed a small reduction in cough frequency compared ...

There is no Morningstar’s Analysis data available. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

Government Executive is government's business news daily and the premier digital destination for senior leaders in the federal government's departments and agencies. Our readers are the high ...

Nov 17 (Reuters) - The U.S. health regulator's advisers on Friday did not recommend Merck's drug for the treatment of chronic cough. The FDA panel voted 12 to 1 that the data presented does not ...

Advertise with us US FDA staff flags concerns on Merck's chronic cough drug FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S ...

(Reuters) -Advisers to the U.S. health regulator said on Friday that data on Merck's chronic cough drug does not provide sufficient evidence to prove its clinical benefit for patients. The U.S ...